226 related articles for article (PubMed ID: 23377530)
1. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions.
Zhang HL; Qin XJ; Cao DL; Zhu Y; Yao XD; Zhang SL; Dai B; Ye DW
Asian J Androl; 2013 Mar; 15(2):231-5. PubMed ID: 23377530
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
3. Serum Levels of miR-223-3p and miR-223-5p in Prostate Diseases.
Dülgeroğlu Y; Eroğlu O
Microrna; 2020; 9(4):303-309. PubMed ID: 33155933
[TBL] [Abstract][Full Text] [Related]
4. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
5. Increased Expression of miR-494 in Serum of Patients with Prostate Cancer and its Potential Diagnostic Value.
Cai B; Peng JH
Clin Lab; 2019 Aug; 65(8):. PubMed ID: 31414754
[TBL] [Abstract][Full Text] [Related]
6. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.
Zhang HL; Yang LF; Zhu Y; Yao XD; Zhang SL; Dai B; Zhu YP; Shen YJ; Shi GH; Ye DW
Prostate; 2011 Feb; 71(3):326-31. PubMed ID: 20842666
[TBL] [Abstract][Full Text] [Related]
7. MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer.
Pang C; Liu M; Fang W; Guo J; Zhang Z; Wu P; Zhang Y; Wang J
Cell Physiol Biochem; 2016; 39(3):1111-7. PubMed ID: 27562849
[TBL] [Abstract][Full Text] [Related]
8. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.
Kachakova D; Mitkova A; Popov E; Popov I; Vlahova A; Dikov T; Christova S; Mitev V; Slavov C; Kaneva R
DNA Cell Biol; 2015 Mar; 34(3):189-200. PubMed ID: 25521481
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment Serum Cystatin C Levels Predict Renal Function, but Not Tumor Characteristics, in Patients with Prostate Neoplasia.
Yang F; Li D; Di Y; Zhang Y; Zang Y; Ren J; Yan L; Zhou Z; Liu H; Xu Z
Biomed Res Int; 2017; 2017():7450459. PubMed ID: 28812020
[TBL] [Abstract][Full Text] [Related]
10. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
11. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
12. Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.
Tumminello FM; Badalamenti G; Incorvaia L; Fulfaro F; D'Amico C; Leto G
Med Oncol; 2009; 26(1):10-5. PubMed ID: 18461289
[TBL] [Abstract][Full Text] [Related]
13. Five microRNAs in serum as potential biomarkers for prostate cancer risk assessment and therapeutic intervention.
Guo X; Han T; Hu P; Guo X; Zhu C; Wang Y; Chang S
Int Urol Nephrol; 2018 Dec; 50(12):2193-2200. PubMed ID: 30324582
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng/mL.
Chang CC; Lee YC; Tsai HW; Yii SC; Yen TH; Chu FY
Asian Pac J Cancer Prev; 2015; 16(13):5261-4. PubMed ID: 26225663
[TBL] [Abstract][Full Text] [Related]
15. Skeletal alkaline phosphatase: a marker for individual follow-up in patients with advanced prostatic cancer.
Wechsel HW; Petri E; Bichler KH
Urol Int; 1997; 58(2):80-3. PubMed ID: 9096267
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. A circulating miRNA assay as a first-line test for prostate cancer screening.
Sharova E; Grassi A; Marcer A; Ruggero K; Pinto F; Bassi P; Zanovello P; Zattoni F; D'Agostino DM; Iafrate M; Ciminale V
Br J Cancer; 2016 Jun; 114(12):1362-6. PubMed ID: 27228285
[TBL] [Abstract][Full Text] [Related]
18. Discovery of extracellular vesicles derived miR-181a-5p in patient's serum as an indicator for bone-metastatic prostate cancer.
Wang Y; Fang YX; Dong B; Du X; Wang J; Wang X; Gao WQ; Xue W
Theranostics; 2021; 11(2):878-892. PubMed ID: 33391510
[No Abstract] [Full Text] [Related]
19. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
Akimoto S; Akakura K; Shimazaki J
Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
[TBL] [Abstract][Full Text] [Related]
20. Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer.
Watahiki A; Macfarlane RJ; Gleave ME; Crea F; Wang Y; Helgason CD; Chi KN
Int J Mol Sci; 2013 Apr; 14(4):7757-70. PubMed ID: 23574937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
